8-K
Jasper Therapeutics, Inc. (JSPR)
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
WASHINGTON,D.C. 20549
FORM 8-K
CURRENTREPORT
PURSUANTTO SECTION 13 OR 15(d) OF THE
SECURITIESEXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 22, 2020
AMPLITUDEHEALTHCARE ACQUISITIONCORPORATION
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-39138 | 84-2984849 |
|---|---|---|
| (State<br> or Other Jurisdiction<br><br> of Incorporation) | (Commission<br><br> File Number) | (IRS<br> Employer<br><br> Identification No.) |
| 1177Avenue of the Americas, FL 40<br><br>New York, New York | 10036 | |
| --- | --- | |
| (Address<br> of Principal Executive Offices) | (Zip<br> Code) |
Registrant’s telephone number, including area code:(212) 823-1900
NotApplicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
| ☐ | Written<br>communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br>material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement<br>communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement<br>communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Titleof each class | Trading<br><br>Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Units,<br> each consisting of one share of Class A Common Stock and one-half of one Redeemable Warrant | AMHCU | The<br> NASDAQ Stock Market LLC |
| Class<br> A Common Stock, par value $0.0001 per share | AMHC | The<br> NASDAQ Stock Market LLC |
| Warrants,<br> each whole warrant exercisable for one share of Class A Common Stock for $11.50 per share | AMHCW | The<br> NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
|---|
On December 22, 2020, Amplitude Healthcare Acquisition Corporation (the “Company”) held its 2020 annual meeting of stockholders (the “Meeting”). At the Meeting, stockholders (i) re-elected two directors to serve as the Class I directors on the Company’s board of directors (“Board”) until the 2023 annual meeting of stockholders or until their successors are duly elected and qualified and (ii) ratified the selection by the audit committee of the Board of WithumSmith+Brown, PC (“Withum”) to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2020.
Set forth below are the final voting results for each of the proposals:
ProposalNo. 1 – Election of directors
Peter Dolan and Glenn Reicin were re-elected to serve as the Class I directors. The voting results were as follows:
| For | Against | Abstain | Broker Non-Votes | |
|---|---|---|---|---|
| Peter Dolan | 2,500,000 | 0 | 0 | N/A |
| Glenn Reicin | 2,500,000 | 0 | 0 | N/A |
ProposalNo. 2 – Ratification of independent registered public accounting firm
The stockholders ratified the selection of Withum to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2020. The voting results were as follows:
| For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|
| 9,132,167 | 0 | 151 | N/A |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 29, 2020
| AMPLITUDE HEALTHCARE ACQUISITION CORPORATION | |
|---|---|
| By: | /s/<br> Bala Venkataraman |
| Name: | Bala Venkataraman |
| Title: | Chief Executive Officer |
2